Orly Vardeny
University of Minnesota-Twin Cities
H-index: 50
North America-United States
Top articles of Orly Vardeny
Cause-Specific Healthcare Costs Following Hospitalization for Heart Failure and Cost Offset with SGLT2 Inhibitor Therapy
JACC: Heart Failure
2024/4/6
Orly Vardeny
H-Index: 25
ANTIBODY RESPONSE TO HIGH-DOSE TRIVALENT VS STANDARD-DOSE QUADRIVALENT INFLUENZA VACCINE IN PATIENTS WITH HIGH-RISK CARDIOVASCULAR DISEASE: THE INVESTED TRIAL
Journal of the American College of Cardiology
2024/4/2
TOTAL AND CAUSE-SPECIFIC HEALTHCARE COSTS FOLLOWING HOSPITALIZATION FOR HEART FAILURE WITH REDUCED VS MILDLY REDUCED/PRESERVED EJECTION FRACTION
Journal of the American College of Cardiology
2024/4/2
James Mcdermott
H-Index: 17
Orly Vardeny
H-Index: 25
CLINICAL TRIAL INCLUSION AND IMPACT ON EARLY ADOPTION OF MEDICAL INNOVATION IN DIVERSE POPULATIONS: A REAL-WORLD CASE STUDY IN PATIENTS WITH HEART FAILURE
Journal of the American College of Cardiology
2024/4/2
Allison Connolly
H-Index: 1
Orly Vardeny
H-Index: 25
Sex Differences in Heart Failure with Improved Ejection Fraction: The DELIVER Trial
Journal of the American College of Cardiology
2024/4/2
TRAJECTORY OF EJECTION FRACTION AMONG PATIENTS WITH HEART FAILURE WITH IMPROVED EJECTION FRACTION
Journal of the American College of Cardiology
2024/4/2
Orly Vardeny
H-Index: 25
Selcuk Adabag
H-Index: 29
SACUBITRIL/VALSARTAN, TREATMENT-RELATED HYPOTENSION, AND LEFT VENTRICULAR EJECTION FRACTION IN THE PARAGON-HF TRIAL
Journal of the American College of Cardiology
2024/4/2
A CALL TO ACTION: HOW CAN CONGRESS HELP ENHANCE DIVERSITY IN CLINICAL TRIALS?
Journal of the American College of Cardiology
2024/4/2
EFFECT OF SACUBITRIL/VALSARTAN ACCORDING TO POLYPHARMACY STATUS IN PARAGON-HF
Journal of the American College of Cardiology
2024/4/2
Feasibility and findings of including self-identified adult congenital heart disease patients in the INVESTED trial
JACC: Advances
2024/4/1
Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER trial
Heart Failure
2024/4/1
Orly Vardeny
H-Index: 25
Sacubitril/Valsartan-Related Hypotension in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction
Journal of the American College of Cardiology
2024/3/25
Milton Packer
H-Index: 81
Orly Vardeny
H-Index: 25
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review
2024/3/5
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the …
Journal of the American Heart Association
2024/2/23
Inder S Anand
H-Index: 47
Orly Vardeny
H-Index: 25
Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of …
JAMA cardiology
2024/2/1
Natural language processing for adjudication of heart failure in a multicenter clinical trial: a secondary analysis of a randomized clinical trial
JAMA cardiology
2024
Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines–Heart Failure Registry
Journal of cardiac failure
2024/2/1
Orly Vardeny
H-Index: 25
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF‐REVERT trial
European Journal of Heart Failure
2024/1/25
Gerasimos Filippatos
H-Index: 105
Orly Vardeny
H-Index: 25
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial
JAMA cardiology
2024/1/24
Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial
JAMA cardiology
2024/4/7
